A potential limitation of our study is its retrospective design; however, the strength is the large sample size, the well-defined patient population, the evaluation at diagnosis, and the long follow-up period. The frequencies of events in our study were similar to those reported in the Cyto-PV 2 study and generally lower than those reported in the ECLAP 4 study. It is possible that this reflects a change of clinical epidemiology in contemporary PV patients, but note that these different studies are not necessarily comparable, although earlier diagnosis and treatment, improved management of cardiovascular risk factors, and more appropriate use of cytoreductive drugs, aspirin, and phlebotomy might have contributed to the improved outcome in this study. Regardless, such details are important to consider for future clinical trials in PV. Of note, patients with a prior venous thrombosis had a more frequent subsequent recurrence in the venous district but a proportion of them (39%) also experienced arterial events and vice versa. This finding may have practical implications and suggests antiplatelet therapy and anticoagulant therapy (vitamin K antagonists or direct factor X inhibitors) as the favorite choice to prevent arterial and venous thrombosis, respectively, but also suggests studies of antithrombotic drug combinations. In this regard, statins that are specifically targeted to prevent arterial thrombosis and also seem promising for reducing risk of venous thrombosis 6 may be candidates to be tested in addition to recommended therapy. The concept of combination therapy is further supported by the fact that currently reported rates of recurrent thrombosis in PV have not improved that much over those reported in much earlier Polycythemia Vera Study Group studies. To the editor:
Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL Diagnostic assessment of a 33-year-old man with T-ALL revealed high leukemic blast expression of HOXA9 at levels comparable to those in known HOXA 1 cases ( Figure 1A ). Tests for PICALM-MLLT10, SET-NUP214, MLL-AF6, and TCRB-HOXA were negative. Leukemic cells exhibited a complex karyotype (46,XY,add(2)(p14),-10,-17,12mars,inc[11]), which led us to speculate that HOXA positivity might be caused by a structural genetic abnormality. We therefore performed poly(A)-enriched sequencing (RNA-sequencing) of diagnostic RNA, analysis of which revealed fusion of exon 24 of XPO1 to exon 6 of MLLT10 ( Figure 1B Figure 1D ), suggesting rarity and/or breakpoint heterogeneity. Each of the genes involved in this fusion has been previously implicated in leukemia. Notably, MLLT10 (which encodes the AF10 protein) is involved in the recurrent PICALM-MLLT10 3 and MLL-MLLT10 4 translocations in both T-ALL and acute myeloblastic leukemia. Recently reported results of RNA-sequencing have identified HNRNPH1 and DDX3X as MLLT10 fusion partners in HOXA 1 T-ALL. 5 Our data provide further evidence of shared fusion partner-independent mechanisms of AF10-mediated transcriptional dysregulation, and this case adds to the repertoire of MLL and/or AF10-rearranged T-ALL that might be candidates for targeted DOT1L-directed therapy.
6 MLLT10 breakpoints are heterogeneous, and increasing truncation of the transcript was reported to correlate with an earlier maturation block in T-ALL, although this was not confirmed in a later series. 3, 7 In this case, detailed characterization of T-cell receptor (TR) gene configuration revealed monoallelic TRG and TRD and incomplete TRB diversityjoining rearrangements (data not shown), consistent with an immature pre-b-selection immunogenotype. 8 XPO1 (also CRM1) encodes exportin 1, a transport protein that mediates nuclear export of multiple tumor suppressor and growth regulatory molecules (eg, P53 and RB1). Pharmacologic XPO1 inhibition has shown promising antileukemic activity in preclinical models via a mechanism that is believed to involve either nuclear retention of XPO1 cargo upon which the leukemic cells depend for survival, 9 and/or reactivation of nuclear protein phosphatase 2A.
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It is tempting to speculate that HOXA-independent activity of the XPO1-AF10 fusion protein could also contribute to leukemogenesis in this case, for example through aberrant transport of proteins that mediate proliferation and survival and/or by dominant negative inhibition of wild-type XPO1.
